A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer

Yuh Min Chen, Reury P. Perng, Kuang Y. Yang, Wei C. Lin, Hsiao W. Wu, Jacqueline M. Liu, Chun M. Tsai, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin (TIEP) chemotherapy was conducted in patients with chemonaive inoperable non- small-cell lung cancer (NSCLC) to assess response and toxicity. From October 1997 to August 1998, 19 patients were treated. The treatment schema included tamoxifen 60 mg twice daily by mouth on days 1 to 3, ifosfamide 3 g/m2 intravenous infusion (IV) 60 minutes with mesna on day 2, epirubicin 50 mg/m2 IV bolus on day 2, and cisplatin 60 mg/m2 IV 60 minutes on day 2 every 4 weeks for up to six cycles. All patients were evaluable for response and toxicity. The major toxicity was myelosuppression; grade 3 or 4 leukopenia or neutropenia occurred in 14 of 19 (73.7%) patients during treatment, and 6 patients (31.6%) experienced fever in association with the neutropenia; no toxic deaths occurred. Grade 3 anemia occurred in six patients (31.6%) during the treatment. Grade 3 or 4 nausea/vomiting occurred in only one patient. Toxicities other than neutropenia and anemia were minimal. After two cycles of treatment, 9 of 19 patients attained a partial response (47.4%, 95% confidence interval 24.9%-69.9%) in this study. The median time to disease progression was 6 months and median survival time was 12 months. We conclude that TIEP is an active combination regimen with an acceptable toxicity profile in Chinese patients with inoperable NSCLC.

Original languageEnglish
Pages (from-to)13-17
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume23
Issue number1
DOIs
Publication statusPublished - Feb 1 2000
Externally publishedYes

Fingerprint

Epirubicin
Ifosfamide
Tamoxifen
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Cisplatin
Neutropenia
Intravenous Infusions
Anemia
Mesna
Poisons
Leukopenia
Therapeutics
Nausea
Vomiting
Mouth
Disease Progression
Fever
Confidence Intervals
Drug Therapy

Keywords

  • Cisplatin
  • Epirubicin
  • Ifosfamide
  • Non-small-cell lung cancer
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer. / Chen, Yuh Min; Perng, Reury P.; Yang, Kuang Y.; Lin, Wei C.; Wu, Hsiao W.; Liu, Jacqueline M.; Tsai, Chun M.; Whang-Peng, Jacqueline.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 23, No. 1, 01.02.2000, p. 13-17.

Research output: Contribution to journalArticle

Chen, Yuh Min ; Perng, Reury P. ; Yang, Kuang Y. ; Lin, Wei C. ; Wu, Hsiao W. ; Liu, Jacqueline M. ; Tsai, Chun M. ; Whang-Peng, Jacqueline. / A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2000 ; Vol. 23, No. 1. pp. 13-17.
@article{cb7c33e506d24417894505f6ce7ec1fb,
title = "A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer",
abstract = "A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin (TIEP) chemotherapy was conducted in patients with chemonaive inoperable non- small-cell lung cancer (NSCLC) to assess response and toxicity. From October 1997 to August 1998, 19 patients were treated. The treatment schema included tamoxifen 60 mg twice daily by mouth on days 1 to 3, ifosfamide 3 g/m2 intravenous infusion (IV) 60 minutes with mesna on day 2, epirubicin 50 mg/m2 IV bolus on day 2, and cisplatin 60 mg/m2 IV 60 minutes on day 2 every 4 weeks for up to six cycles. All patients were evaluable for response and toxicity. The major toxicity was myelosuppression; grade 3 or 4 leukopenia or neutropenia occurred in 14 of 19 (73.7{\%}) patients during treatment, and 6 patients (31.6{\%}) experienced fever in association with the neutropenia; no toxic deaths occurred. Grade 3 anemia occurred in six patients (31.6{\%}) during the treatment. Grade 3 or 4 nausea/vomiting occurred in only one patient. Toxicities other than neutropenia and anemia were minimal. After two cycles of treatment, 9 of 19 patients attained a partial response (47.4{\%}, 95{\%} confidence interval 24.9{\%}-69.9{\%}) in this study. The median time to disease progression was 6 months and median survival time was 12 months. We conclude that TIEP is an active combination regimen with an acceptable toxicity profile in Chinese patients with inoperable NSCLC.",
keywords = "Cisplatin, Epirubicin, Ifosfamide, Non-small-cell lung cancer, Tamoxifen",
author = "Chen, {Yuh Min} and Perng, {Reury P.} and Yang, {Kuang Y.} and Lin, {Wei C.} and Wu, {Hsiao W.} and Liu, {Jacqueline M.} and Tsai, {Chun M.} and Jacqueline Whang-Peng",
year = "2000",
month = "2",
day = "1",
doi = "10.1097/00000421-200002000-00003",
language = "English",
volume = "23",
pages = "13--17",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer

AU - Chen, Yuh Min

AU - Perng, Reury P.

AU - Yang, Kuang Y.

AU - Lin, Wei C.

AU - Wu, Hsiao W.

AU - Liu, Jacqueline M.

AU - Tsai, Chun M.

AU - Whang-Peng, Jacqueline

PY - 2000/2/1

Y1 - 2000/2/1

N2 - A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin (TIEP) chemotherapy was conducted in patients with chemonaive inoperable non- small-cell lung cancer (NSCLC) to assess response and toxicity. From October 1997 to August 1998, 19 patients were treated. The treatment schema included tamoxifen 60 mg twice daily by mouth on days 1 to 3, ifosfamide 3 g/m2 intravenous infusion (IV) 60 minutes with mesna on day 2, epirubicin 50 mg/m2 IV bolus on day 2, and cisplatin 60 mg/m2 IV 60 minutes on day 2 every 4 weeks for up to six cycles. All patients were evaluable for response and toxicity. The major toxicity was myelosuppression; grade 3 or 4 leukopenia or neutropenia occurred in 14 of 19 (73.7%) patients during treatment, and 6 patients (31.6%) experienced fever in association with the neutropenia; no toxic deaths occurred. Grade 3 anemia occurred in six patients (31.6%) during the treatment. Grade 3 or 4 nausea/vomiting occurred in only one patient. Toxicities other than neutropenia and anemia were minimal. After two cycles of treatment, 9 of 19 patients attained a partial response (47.4%, 95% confidence interval 24.9%-69.9%) in this study. The median time to disease progression was 6 months and median survival time was 12 months. We conclude that TIEP is an active combination regimen with an acceptable toxicity profile in Chinese patients with inoperable NSCLC.

AB - A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin (TIEP) chemotherapy was conducted in patients with chemonaive inoperable non- small-cell lung cancer (NSCLC) to assess response and toxicity. From October 1997 to August 1998, 19 patients were treated. The treatment schema included tamoxifen 60 mg twice daily by mouth on days 1 to 3, ifosfamide 3 g/m2 intravenous infusion (IV) 60 minutes with mesna on day 2, epirubicin 50 mg/m2 IV bolus on day 2, and cisplatin 60 mg/m2 IV 60 minutes on day 2 every 4 weeks for up to six cycles. All patients were evaluable for response and toxicity. The major toxicity was myelosuppression; grade 3 or 4 leukopenia or neutropenia occurred in 14 of 19 (73.7%) patients during treatment, and 6 patients (31.6%) experienced fever in association with the neutropenia; no toxic deaths occurred. Grade 3 anemia occurred in six patients (31.6%) during the treatment. Grade 3 or 4 nausea/vomiting occurred in only one patient. Toxicities other than neutropenia and anemia were minimal. After two cycles of treatment, 9 of 19 patients attained a partial response (47.4%, 95% confidence interval 24.9%-69.9%) in this study. The median time to disease progression was 6 months and median survival time was 12 months. We conclude that TIEP is an active combination regimen with an acceptable toxicity profile in Chinese patients with inoperable NSCLC.

KW - Cisplatin

KW - Epirubicin

KW - Ifosfamide

KW - Non-small-cell lung cancer

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0034122378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034122378&partnerID=8YFLogxK

U2 - 10.1097/00000421-200002000-00003

DO - 10.1097/00000421-200002000-00003

M3 - Article

C2 - 10683066

AN - SCOPUS:0034122378

VL - 23

SP - 13

EP - 17

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -